Custom Criteria for
BlueCross Blue Shield of Rhode Island Commercial

DYSPORT (AbobotulinumtoxinA)

## GPI CODING:

74400020******

## DESCRIPTION:

AbobotulinumtoxinA (DYSPORT™) is a botulinum neurotoxin product produced by the spore-forming anaerobic bacillus *Clostridium botulinum* type A. Botulinum toxins inhibit the release of acetylcholine from cholinergic junctions, causing functional denervation of the muscle that results in a localized reduction of muscle activity. Botulinum toxin type A products, like DYSPORT, specifically inhibit acetylcholine release by cleaving the synaptosomal-associated protein of 25-kilodaltons (SNAP-25), which is important for the successful binding and release of acetylcholine in the nerve endings. Recovery of transmission occurs gradually as the neuromuscular junction recovers from SNAP25 cleavage and as new nerve endings are formed.

## APPROVAL DURATION:

Approval duration: lifetime

## CRITERIA FOR DYSPORT:

Patient has a diagnosis for one of the following:

I. Achalasia in patients who have experienced failure of or are poor surgical candidates for myotomy and cannot accept the risks associated with pneumatic dilation (e.g. esophageal perforation)
II. Anal fissure, chronic, in patients who have experienced failure of conservative therapy (including increased liquid and fiber intake, stool softeners, and topical nitroglycerin)
III. Axillary or palmar hyperhidrosis that significantly interferes with patient's daily activities and refractory to >6 months treatment with topical aluminum chloride
IV. Blepharospasm
V. Cervical dystonia (including spasmodic torticollis)
VI. Hemifacial spasm
VII. Sialorrhea (drooling/ptyalism or excessive salivation) associated with neurological disorders (i.e. amyotrophic lateral sclerosis, cerebral palsy, Parkinson's disease)
VIII. Spasticity (upper or lower limb) from ANY of the following causes:
    a. Cerebral palsy
    b. Demyelinating disorders of the central nervous system
    c. Hereditary paraplegia
    d. Multiple sclerosis
    e. Spinal cord injury
    f. Stroke
    g. Traumatic brain injury

Patient does not have any of the following contraindications to therapy:

IX. Allergy to cow's milk protein
X. Hypersensitivity to human albumin
XI. Presence of infection at the proposed injection site(s)